Table 1 Baseline clinical characteristics
All population | Diabetes | Small vessel | CTO | AMI | |
|---|---|---|---|---|---|
N = 150 | N = 48 | N = 75 | N = 17 | N = 80 | |
Age, years | 67.2 ± 12.5 | 69.7 ± 10.0 | 65.8 ± 13.6 | 65.4 ± 15.3 | 65.2 ± 13.7 |
Men | 102(68.0) | 30(63.8) | 46(62.2) | 11(64.7) | 57(71.3) |
Current smokers | 20(13.3) | 3(6.4) | 10(13.5) | 4(23.5) | 17(18.8) |
Diabetes | 48(32.0) | n/a | 27(36.5) | 6(35.3) | 21(26.3) |
Hypertension | 113(75.3) | 42(89.4) | 58(78.4) | 13(76.5) | 56(70.0) |
Hyperlipidemia | 96(64.0) | 34(72.3) | 49(66.2) | 10(58.8) | 42(52.5) |
Chronic kidney disease | 27(18.0) | 15(31.9) | 12(16.2) | 5(29.4) | 15(18.8) |
Chronic obstructive pulmonary disease | 5(3.3) | 1(2.1) | 1(1.4) | 1(5.9) | 2(2.5) |
Previous coronary revascularization | 27(18.0) | 12(25.5) | 16(21.6) | 5(29.4) | 6(7.5) |
Previous myocardial infarction | 27(18.0) | 11(23.4) | 12(16.2) | 3(17.6) | 13(16.3) |
History of heart failure | 18(12.0) | 6(12.8) | 10(13.5) | 3(17.6) | 10(12.5) |
History of cancer | 3(2.0) | 1(2.1) | 3(4.1) | 2(11.8) | 2(2.5) |
Chronic coronary syndrome | 70(46.7) | 26(55.3) | 40(54.1) | 8(47.1) | 0(0.0) |
Acute coronary syndrome | 80(53.3) | 21(44.7) | 34(45.9) | 9(52.9) | 80(100.0) |
ST segment elevation MI | 40(50.0) | 6(28.6) | 19(55.9) | 6(66.7) | 40(50.0) |
Non ST segment elevation MI | 40(50.0) | 15(71.4) | 15(44.1) | 3(33.3) | 40(50.0) |
Medication at discharge | |||||
Aspirin | 147(98) | 45(95.7) | 72(97.3) | 16(94.1) | 78(97.5) |
Clopidogrel | 89(59.7) | 33(70.2) | 44(59.5) | 9(52.9) | 36(45.6) |
Ticagrelor | 49(33.8) | 13(28.3) | 23(32.9) | 4(23.5) | 38(48.7) |
Prasugrel | 11(7.5) | 1(2.2) | 7(9.9) | 3(17.6) | 5(6.4) |
Statin | 140(94.0) | 44(93.6) | 69(93.2) | 16(94.1) | 72(91.1) |
DAPT at 12 months | 121(87.1) | 36(83.7) | 60(88.2) | 15(100.0) | 69(92.0) |